Last updated: 2026-09-09 19:20:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
MacroGenics, Inc. (MGNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.12, with a market capitalisation of $280.28M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.29 to $5.08. This page covers its latest market performance, valuation, price trends and company information.
$280.28M | |
$4.36 | |
$41.00 | |
$0.99 | |
$4.32 | |
382.39K | |
850.50K | |
-- | |
$5.08 | |
$1.29 | |
-- | |
-- |
MacroGenics, Inc. (MGNX) is currently trading at $4.12 as of 2026-09-09 19:04:17, down 4.75% ($0.21) from the previous close of $4.32
During today's regular trading session, MGNX has traded between $0.99 and $41.00, with a trading volume of 382.39K shares. The current price is near the lower end of today's range.
Over the past seven days, MacroGenics, Inc. (MGNX) moved from $4.13 to $4.12, representing a decline of 0.36% ($0.01).
The stock traded between $3.89 and $4.49 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 501.00 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 74.5%
MGNX is currently trading at $4.12, placing it 74.5% of the way from its 52-week low of $1.29 to its 52-week high of $5.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 293 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MacroGenics, Inc. (MGNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.